How did ARMP's revenue and expenses trend in Q4 2024?

Armata Pharmaceuticals (ARMP) experienced a significant increase in revenue, with a reported $5.17 million in the fourth quarter of 2024, compared to $3.94 million in the same period the previous year. However, the company's operating expenses remained relatively stable at approximately $1.24 million. This led to a notable improvement in net income, with the company reporting $2.6 million in profit for Q4 2024, up from $2.6 million in net income in Q4 2023.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|ARMP|ARMP.A|Armata Pharmaceuticals|20240101-2024|Grant|5174000|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|20240101-2024|Grant|3939000|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|20240101-2024|Grant|966000|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|20240101-2024|Grant|966000|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|20240101-2024|Grant|966000|170|

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|Operating Expenses|Net Income|market_code|
|---|---|---|---|---|---|---|---|---|
|ARMP|ARMP.A|Armata Pharmaceuticals|2023 Q4|45.38534728829686|1528000||-1.9847E7|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|2024 Q1|21.35678391959799|966000||-2.5021E7|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|2024 Q2||||8986000|170|
|ARMP|ARMP.A|Armata Pharmaceuticals|2024 Q3|142.69387755102042|2973000||-5481000|170|